$SAGE
Sage Therapeutics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000119312514410228 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.400M $2.900M $1.100M
YoY Change 183.33% 163.64%
% of Gross Profit
Research & Development $8.900M $6.601M $3.408M
YoY Change 97.78% 93.69%
% of Gross Profit
Depreciation & Amortization $100.0K $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $12.36M $9.471M $4.519M
YoY Change 116.86% 109.58%
Operating Profit -$12.36M -$9.471M -$4.519M
YoY Change 109.58%
Interest Expense $0.00 $3.000K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 -$1.000K $0.00
YoY Change
Pretax Income -$12.40M -$9.500M -$4.500M
YoY Change 117.54% 111.11%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.36M -$9.468M -$4.519M
YoY Change 116.86% 109.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$574.1K -$484.7K -$187.5K
COMMON SHARES
Basic Shares Outstanding 25.79M shares 19.58M shares 1.515M shares
Diluted Shares Outstanding 19.58M shares 1.515M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.8M $136.7M
YoY Change 1477.78%
Cash & Equivalents $127.8M $136.7M $12.84M
Short-Term Investments
Other Short-Term Assets $1.100M $1.100M
YoY Change 266.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $128.8M $137.8M
YoY Change 1432.32%
LONG-TERM ASSETS
Property, Plant & Equipment $163.0K $134.0K
YoY Change 89.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $0.00
YoY Change
Total Long-Term Assets $843.0K $173.0K
YoY Change 574.4%
TOTAL ASSETS
Total Short-Term Assets $128.8M $137.8M
Total Long-Term Assets $843.0K $173.0K
Total Assets $129.7M $138.0M
YoY Change 1419.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.429M $2.157M
YoY Change 22.18%
Accrued Expenses $4.687M $2.853M
YoY Change 1333.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.757M $5.010M
YoY Change 235.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $23.00K $34.00K
YoY Change -47.73%
Total Long-Term Liabilities $23.00K $34.00K
YoY Change -47.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.757M $5.010M
Total Long-Term Liabilities $23.00K $34.00K
Total Liabilities $7.780M $5.044M
YoY Change 229.8%
SHAREHOLDERS EQUITY
Retained Earnings -$66.85M -$54.48M
YoY Change 111.03%
Common Stock $188.7M $3.000K
YoY Change 135676.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.9M $132.9M
YoY Change
Total Liabilities & Shareholders Equity $129.7M $138.0M
YoY Change 1419.75%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$12.36M -$9.468M -$4.519M
YoY Change 116.86% 109.52%
Depreciation, Depletion And Amortization $100.0K $0.00 $0.00
YoY Change
Cash From Operating Activities -$8.600M -$7.500M -$5.200M
YoY Change 72.0% 44.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$100.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -200.0K 95.10M 17.50M
YoY Change -166.67% 443.43%
NET CHANGE
Cash From Operating Activities -8.600M -7.500M -5.200M
Cash From Investing Activities 0.000 -100.0K 0.000
Cash From Financing Activities -200.0K 95.10M 17.50M
Net Change In Cash -8.800M 87.50M 12.30M
YoY Change 87.23% 611.38%
FREE CASH FLOW
Cash From Operating Activities -$8.600M -$7.500M -$5.200M
Capital Expenditures $0.00 -$100.0K $0.00
Free Cash Flow -$8.600M -$7.400M -$5.200M
YoY Change 72.0% 42.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25792623 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12844000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25586295 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25586295 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70623905 shares
CY2014Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2014Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2014Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3408000
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5010000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2157000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54484000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2853000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
132919000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
153000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137963000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187400000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
471000
CY2014Q3 us-gaap Liabilities
Liabilities
5044000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
837000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136727000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
134000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1063000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
39000
CY2014Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2281000
CY2014Q3 us-gaap Assets
Assets
137963000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
137790000
CY2014Q3 sage Accrued Clinical And Development Expenses
AccruedClinicalAndDevelopmentExpenses
1392000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2802000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1622761 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1622761 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
66000000 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
37750000 shares
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
37750000 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
37750000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
37709000
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
40663000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2315000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1988000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31675000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
327000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-31536000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8532000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139000
CY2013Q4 us-gaap Liabilities
Liabilities
2359000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
190000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
39000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
49000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8066000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
341000
CY2013Q4 us-gaap Assets
Assets
8532000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
8407000
CY2013Q4 sage Accrued Clinical And Development Expenses
AccruedClinicalAndDevelopmentExpenses
57000
CY2014Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3174 pure
CY2014Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
18007575 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12477000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1467387 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1467387 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.56
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6934862 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1467387 shares
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
311000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12564000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12563000
us-gaap Net Income Loss
NetIncomeLoss
-12563000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34000
us-gaap Operating Expenses
OperatingExpenses
12564000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9845000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10042000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
22522000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
371000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
37000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2719000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-40000
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Trading Symbol
TradingSymbol
SAGE
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P10Y
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18375000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4D
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In connection with preparing for the IPO, the Company's board of directors and stockholders approved a 1-for-3.15 reverse stock split of the Company's common stock
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0190 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7711038 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7711038 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
shares
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0107 pure
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1783209 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7711038 shares
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
722000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21449000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-2294000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
92863000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23744000
us-gaap Net Income Loss
NetIncomeLoss
-21450000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1186000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
127000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1186000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
35000
us-gaap Operating Expenses
OperatingExpenses
21449000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15155000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
128661000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2294000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
147119000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
92863000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2455000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-83000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
39000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6294000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
96255000
sage Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate
0.10 pure
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1111000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
sage Payment Of Offering Costs
PaymentOfOfferingCosts
2035000
sage Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2014-07-02
sage Licensing Or Consultant Fees Paid In Common Stock
LicensingOrConsultantFeesPaidInCommonStock
127000
sage Deferred Initial Public Offering Costs Included In Current Liabilities
DeferredInitialPublicOfferingCostsIncludedInCurrentLiabilities
246000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M16D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0199 pure
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19581624 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19581624 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0043 pure
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1783209 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19581624 shares
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9470000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9859000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-9468000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
9470000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6601000
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
391000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2869000
CY2014Q3 sage Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate
0.10 pure
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1514838 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1514838 shares
CY2013Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.98
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8938265 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1514838 shares
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4519000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4519000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-4519000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
4519000

Files In Submission

Name View Source Status
0001193125-14-410228-index-headers.html Edgar Link pending
0001193125-14-410228-index.html Edgar Link pending
0001193125-14-410228.txt Edgar Link pending
0001193125-14-410228-xbrl.zip Edgar Link pending
d785749d10q.htm Edgar Link pending
d785749dex311.htm Edgar Link pending
d785749dex312.htm Edgar Link pending
d785749dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20140930.xml Edgar Link completed
sage-20140930.xsd Edgar Link pending
sage-20140930_cal.xml Edgar Link unprocessable
sage-20140930_def.xml Edgar Link unprocessable
sage-20140930_lab.xml Edgar Link unprocessable
sage-20140930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending